We outline the market outlook for decentralized clinical trials software — from market size, to leading companies, to recommendations for players in the space.
What are decentralized clinical trials?
Decentralized clinical trials (DCT) bring clinical research closer to patients, reducing the need for them to visit trial sites.
DCT software helps pharmaceutical companies execute these trials through telemedicine and local healthcare providers. Features like electronic consent and remote patient monitoring allow trial sponsors to maintain links to trial participants without in-person visits.
Although most trials are not yet fully decentralized, this approach results in simplified as well as more flexible trial procedures, enabling sponsors to recruit more targeted and/or larger participant bases.
Features & capabilities
DCT solutions provide pharmaceutical companies with a number of capabilities and tools, including:
- Electronic consent
- Remote patient monitoring and patient engagement
- Electronic clinical outcome assessment (eCOA) — digital solutions that measure and record how a patient is feeling and/or functioning
At a high level, these solutions are focused on reducing operational costs and reliance on paper-based systems in trial execution, improving speed of completion, and augmenting data collection.